Request Demo
Last update 21 May 2026
FH-006
Last update 21 May 2026
Overview
Basic Info
Drug Type Antibody drug conjugate (ADC) |
Synonyms FH-006 |
Target |
Action inhibitors, antagonists |
Mechanism CD276 inhibitors(CD276 antigen inhibitors), EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), TOP1MT inhibitors(DNA topoisomerase I mitochondrial inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Boost your research with our ADC technology data.
login
or
Related
3
Clinical Trials associated with FH-006NCT07241767
An Open Label, Multicenter Phase II Clinical Study on the Safety, Tolerability, and Efficacy of FH-006 Injection Combined With Other Anti-tumor Therapies in Lung Cancer Subjects
NCT07136142
A Multicenter, Open Label Phase I/II Clinical Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of FH-006 for Injection in Patients With Malignant Solid Tumors
NCT06735144
A Multicenter, Open Label Phase I/II Clinical Study on the Safety, Tolerability, Pharmacokinetics, and Efficacy of FH-006 for Injection in Patients With Malignant Solid Tumors
100 Clinical Results associated with FH-006
Login to view more data
100 Translational Medicine associated with FH-006
Login to view more data
100 Patents (Medical) associated with FH-006
Login to view more data
100 Deals associated with FH-006
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Locally Advanced Lung Non-Small Cell Carcinoma | Phase 2 | China | 12 Nov 2025 | |
| Non-Small Cell Lung Cancer | Phase 2 | China | 12 Nov 2025 | |
| Non-Small Cell Lung Cancer | Phase 2 | China | 12 Nov 2025 | |
| Advanced Malignant Solid Neoplasm | Phase 2 | China | 21 Aug 2025 | |
| Advanced Malignant Solid Neoplasm | Phase 2 | China | 21 Aug 2025 | |
| KRAS G12D mutation Solid Tumors | IND Approval | China | 15 Apr 2026 | |
| KRAS G12D mutation Solid Tumors | IND Approval | China | 15 Apr 2026 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free